An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated (the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every two weeks in addition to radiation therapy, and then every four weeks. They will be compared to patients receiving standard therapy with temozolomide in addition to radiation therapy.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02617589.

Trial PhasePhase III

Trial Typetreatment

Lead OrganizationBristol-Myers Squibb

• Primary IDCA209-498
• Secondary IDsNCI-2016-00144, 2015-003739-37
• ClinicalTrials.gov IDNCT02617589